Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

This month we take a look into the history of the global leader in diabetes: Novo Nordisk, which began as two companies before a merger in the 80s. Today, there are over 366 million people living around the world with diabetes. Novo Nordisk prides itself on...

Articles

Bad Pharma? Better laws needed

Paul Gershlick addresses some of the points raised in Ben Goldacre’s book, Bad Pharma, and highlights what needs to change in order to achieve true transparency in the pharmaceutical industry. I have finished reading Ben Goldacre’s Bad Pharma book. I strongly recommend it. Whether you agree or disagree with…

Articles

AstraZeneca’s first direct-to-patient program – one year on

Steven Davis, Executive Director, Foundation Brands, AstraZeneca shares his views on ARIMIDEX Direct – AstraZeneca’s first direct-to-patient program, and how successful its first year has been. A year ago, AstraZeneca announced its first direct-to-patient program in the US, whereby patients with a valid prescription could...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital